Share on LinkedInShare on LinkedIn

ARTICLE · 03 APRIL 2021

Market Intelligence Thought Leadership Award Winner

AI In The Pharmaceutical Industry

Marks & Clerk
Marks & Clerk
Contributor
Marks & Clerk

Marks & Clerk

Marks & Clerk LLP was founded in 1887 by George Croydon Marks, who was joined in partnership by...

View firm profile
Explore more from Marks & Clerk

AI is set to revolutionise how new pharmaceuticals are brought to market. So why aren't the major pharmaceutical companies filing patents to AI-related inventions?

United KingdomIntellectual Property

AI is set to revolutionise how new pharmaceuticals are brought to market. So why aren't the major pharmaceutical companies filing patents to AI-related inventions?

Investment in AI-related research and development has surged in recent years, and AI is increasingly seen as key to the future of innovation in the life sciences. Innovators are now applying AI methods to an enormous range of problems, from modelling biological systems and predicting the efficacy and safety of candidate drugs in early stage drug discovery to symptom evaluation, risk management and diagnostics.

Given the promise and potentially disruptive impacts of AI on the life sciences, it is no surprise that the list of pharmaceutical companies using AI continues to grow. The biggest players in the sector are seeking to unleash the power of AI to boost their pipelines, whether that is through developing AI expertise in house, partnering with companies specialising in AI, or through industry wide

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from